ACBMOTCServices-Amusement & Recreation ServicesUS GAAP · USD

Acro Biomedical Co., LTD.

ACRO BIOMEDICAL CO., LTD. is a Nevada-incorporated microcap company that, following a 2017 change of control, pivoted from its prior business to developing and marketing nutritional products focused on wellness. Historically, it acted primarily as a trading/distribution business: purchasing cordyceps-related supplements from three suppliers in Taiwan and reselling to a small number of distributors/customers, mainly in Taiwan and Hong Kong. The company has not generated any sales since December 31, 2022 and, as of its 2025 filings, reported no orders and no active marketing or distribution arrangements. Operations have been funded largely through advances from a minority stockholder, with substantial going-concern uncertainty disclosed in its reports.

Ask about the company
Revenue0.0m USD
Operating profit (EBIT)-0.2m USD
−305.8 %y/y
Net income-0.1m USD
−139.1 %y/y
Free cash flow-0.2m USD
−435.0 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-20-15-10-505m USD2020: 0.69 m USD2020: EBIT -0.13 m USD20202021: 1.2 m USD2021: EBIT -7.7 m USD20212022: 0.66 m USD2022: EBIT -16 m USD20222023: 0.00 m USD2023: EBIT -8.8 m USD20232024: 0.00 m USD2024: EBIT -0.04 m USD20242025: 0.00 m USD2025: EBIT -0.15 m USD20250.00-0.15
RevenueOperating profit (EBIT)
Ask Clarifo about Acro Biomedical Co., LTD.

Business

Share of revenue
Cordyceps-based supplements90 %

Cordyceps-related wellness products historically purchased from Taiwan suppliers and resold to distributors.

Other nutritional products (non-cordyceps)5 %

Non-cordyceps supplement items sold historically (e.g., metallothionein MT-3 elizer) and potential future complementary products.

R&D / product development initiatives0 %

Exploratory development work (e.g., chicken feed supplement concept) that has not resulted in commercial products.

Sourcing and distribution services (trading model)5 %

Supplier sourcing, import/fulfillment, and wholesale distribution activities supporting product resale.

Customers

Historically, ACRO sold primarily to a very small number of unrelated distributor-type customers rather than directly to end consumers. In 2022, two customers accounted for 100% of revenue (and 91.7% in 2021), highlighting extreme customer concentration and limited negotiating leverage. Customers were based in Taiwan and Hong Kong, and the company notes that these distributors were responsible for regulatory compliance in the countries where they resold products (including Taiwan, China and Hong Kong). As of the 2025 reports, the company had no current orders and no formal customer agreements, meaning any restart would require rebuilding a customer base and channels from scratch.

Supplement distributors (Taiwan)

Purchase cordyceps-related products for wholesale distribution and resale in Taiwan and adjacent markets.

Supplement distributors (Hong Kong / China-linked channels)

Buy products for resale through Hong Kong-based channels with downstream exposure to PRC consumer demand and policy conditions.

Potential new distributors/agents (international)

Prospective channel partners needed to restart sales given the lack of current marketing and distribution arrangements.

Strategy

Near-term strategy is constrained by the absence of orders, inventory purchases since 2022, and reliance on related-party funding, making liquidity and business reactivation prerequisites. Management indicates a need to rebuild marketing and distribution channels and potentially hire sales/marketing personnel, as prior sales were driven by a non-full-time CEO. The product focus remains largely cordyceps-based supplements, with optionality to add complementary products, though no negotiations were underway per the filings. The company also intends to rely on third parties for inspection, verification, testing, and certification if it manufactures or outsources manufacturing, aiming to support compliance and product quality expectations.

Rebuild marketing and distribution channelsShort term

The company reports no current marketing/distribution arrangements and no orders, making channel development essential to restart revenue.

Stabilize financing and liquidityShort term

Operations have been funded primarily by advances from a minority stockholder and the company discloses substantial doubt about going concern.

Broaden product offering beyond cordycepsMedium term

A narrow product set increases sensitivity to changes in public tastes and category-specific demand shocks.

Geography

The company is headquartered in Fishers, Indiana (United States) but historically sourced products from suppliers in Taiwan and sold to customers located in Taiwan and Hong Kong. Management highlights that demand and sell-through were affected by China’s COVID-19 restrictions and political/legal conditions impacting Hong Kong, indicating meaningful indirect exposure to PRC end markets. The operating model depends on cross-border logistics and the ability of distributors to market products under local dietary supplement rules. No authoritative revenue-by-geography percentages were provided in the excerpts, and the company reported no sales since 2022, limiting the usefulness of a quantitative geographic split.

Risks

The dominant company-specific risk is going concern: ACRO has had no revenue since 2022, minimal cash, and relies on advances from a minority stockholder, with no assurance of continued funding. Commercial risk is elevated due to extreme historical customer concentration, lack of customer contracts, and the absence of current marketing/distribution arrangements. The business is also exposed to regulatory and compliance risk across jurisdictions for dietary supplements (labeling, purity, approvals), while product liability exposure is heightened by the disclosure that the company does not carry product liability insurance. Finally, the cross-border supply chain (Taiwan sourcing; China/Hong Kong-linked demand) creates geopolitical, logistics, and demand-disruption risks, including sensitivity to PRC policy actions and inflation/supply chain disruptions.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Going concern and inability to generate revenue1Reliance on related-party funding2Customer concentration and lack of customer agreements3Geopolitical/policy disruption affecting Hong Kong/China-linked demand4Regulatory compliance for dietary supplements across countries5Supply chain and supplier dependency (Taiwan sourcing; no long-term contracts)6Product liability exposure without insurance7
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Going concern and inability to generate revenueImpact: CriticalLikelihood: High

    The company reports no revenues since December 31, 2022, minimal cash, and substantial doubt about continuing as a going concern.

    Exposure: Liquidity/solvency; ability to maintain operations

  2. Reliance on related-party fundingImpact: HighLikelihood: High

    Primary financing has been advances from a minority stockholder (and to a lesser extent the CEO) with no assurance of continuation.

    Exposure: Financing/refinancing risk

  3. Customer concentration and lack of customer agreementsImpact: HighLikelihood: High

    Two customers represented 100% of 2022 revenue and 91.7% of 2021 revenue; customers can cease purchasing at any time.

    Exposure: Revenue continuity and pricing power

  4. Geopolitical/policy disruption affecting Hong Kong/China-linked demandImpact: HighLikelihood: High

    Management cites impacts from China’s COVID-19 restrictions and political/legal situation in Hong Kong on sales and fundraising.

    Exposure: Demand disruption and channel instability

  5. Regulatory compliance for dietary supplements across countriesImpact: HighLikelihood: Medium

    Each country has laws on purity, labeling, and approvals; inability to comply can block sales or trigger enforcement actions.

    Exposure: Market access and compliance costs

  6. Supply chain and supplier dependency (Taiwan sourcing; no long-term contracts)Impact: MediumLikelihood: High

    No long-term supplier agreements and potential interruptions (transport, disasters) can raise costs or limit availability.

    Exposure: COGS volatility and ability to fulfill orders

  7. Product liability exposure without insuranceImpact: MediumLikelihood: Low

    The company discloses it does not have product liability insurance, increasing financial impact of any claims.

    Exposure: Legal liabilities and cash drain

Ask Clarifo about Acro Biomedical Co., LTD.

Accounting

Judgemental items
Credit loss / bad debt provisioning (allowance for doubtful accounts)

The company recorded a $480,000 bad debt reserve in 2023 for receivables from 2022 sales deemed uncollectible, showing high estimation risk.

Impact: Can materially distort operating results and working-capital metrics in low-revenue periods.

Related-party financing and imputed interest

Operations have been funded by advances from a minority stockholder and the company reports imputed interest on related-party balances.

Impact: Non-cash interest expense and liability balances may be significant relative to the company’s scale.

Lease accounting (operating lease liability movements)

Cash flow discussion references changes in operating lease liabilities, indicating lease accounting affects period-to-period comparability.

Impact: Impacts balance sheet leverage measures and operating cash flow reconciliation.

Similar listed companies

Publicly listed companies with a comparable business focus.

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

BioCorRx Inc.

BICX · Services-Specialty Outpatient Facilities, NEC

BioVie Inc

BIVIW · Pharmaceutical Preparations

Cero Therapeutics Holdings, Inc.

CEROW · Biological Products, (No Diagnostic Substances)

Aardvark Therapeutics, Inc.

AARD · Pharmaceutical Preparations

Keros Therapeutics, Inc.

KROS · Pharmaceutical Preparations

Last updated: 24/09/2026